Trials / Completed
CompletedNCT00225719
Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL
Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- CSL Limited · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inability to achieve reversal of the atherosclerotic process; and poor patient compliance due to chronicity of therapy. This study will assess the effects of rHDL compared with placebo on indices of atherosclerosis progression and regression as assessed with intravascular ultrasound (IVUS) in patients after acute coronary syndromes (ACS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rHDL |
Timeline
- Start date
- 2005-07-01
- First posted
- 2005-09-26
- Last updated
- 2008-11-10
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00225719. Inclusion in this directory is not an endorsement.